ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

TLGG White Paper Reveals the Future of Clinical Trials is Digital; Advises Stakeholders to Prepare Now

--News Direct--

TLGG Consulting, an award-winning management consultancy with a focus on digital strategy, business model innovation and organizational transformation, today released a new white paper: The Future of Clinical Trials is Digital: Are you Ready? The report explains that digital clinical trials (DCTs) are expanding, and are set to improve upon outdated and inefficient processes in traditional clinical research with improved access, retention, analysis and optimization in trial methods, and disrupt the existing medical research ecosystem.

DCTs use novel digital technologies or processes to enable participation outside of conventional clinical settings. The report describes that traditional clinical research processes to develop new medical technologies are plagued by steep costs, lengthy timelines, and high rates of failure, delaying the development of urgently needed new technologies and contributing to increased prices of new products that are successfully developed.

In response to outdated systems, benefits of DCTs include:

  • Improved Recruitment: Digital tools can open paths to new and more diverse participant subpopulations, improving the equity of medical research.

  • Increased Retention of Trial Participants: Patient-centric innovations that reduce participant drop-out and lead to quicker trial completion include fewer visits to trial sites, clearer explanations of the trial process, improved communication between researcher and participant, and less burdensome and more automated self-reporting.

  • Improved Data Collection and Analysis: Digital tools and technologies, including automated monitoring and wearables, lead to more regular, robust, and reliable capture of safety and efficacy data.

  • Optimized Trial Methods and Designs: Digital tools will enable advanced analysis of trial operations to help determine the most effective methods of participant engagement. DCTs, and their associated cost-savings, could enable product developers to embrace new approaches to research and risk tolerance, and allow them to conduct a wider range of activities in-house.

Katrin Zimmermann, Managing Director of the Americas at TLGG Consulting, said, “The healthcare industry is evolving at an exponential rate and innovative digital technologies and methodologies can improve the development of new drugs, vaccines, and diagnostics. TLGG’s analysis of today’s clinical trial landscape indicates there are great opportunities to increase the speed of research, reduce its cost, and alleviate many of the burdens traditionally associated with participating in a clinical trial. However, the adoption of these trends will have a significant impact on pharma and other research organizations--new business models, skill sets, and team structures will be required to fully leverage the potential of digital trials.”

According to TLGG, the implications of the growing role of DCTs in clinical research are diverse and will impact several stakeholder groups, prompting the need for new business models, new partnerships, new operational processes, and increased prioritization of innovations that focus on improving trial participant experiences. Those impacted will include:

  • Product Developers: pharmaceutical companies,

  • Trial Centers: hospitals, universities, and contract research organizations (CROs).

  • Digital Experts, Service Providers, and Entrepreneurs.

Analysis suggests that current clinical research stakeholders should prepare for an increasingly digital trial ecosystem. In doing so, impacted groups are likely to benefit from guidance relating to digitization and optimization of products, services and systems to improve user experiences.

For more information or to view the full white paper, please visit www.tlggconsulting.com/dct-white-paper/.

About TLGG

TLGG Consulting is a strategy consultancy for the digital age, with a growing team of 50+ digital experts, created in 2018 and spun off from the digital and creative agency TLGG and locations in Berlin and New York. TLGG accompanies organizations and companies through change with a holistic digital approach in all business processes. Their guiding principle is that unique business models require unique solutions. Companies and institutions such as Aurelis, Deutsche Bahn, Lufthansa, Schmitz Cargobull, dena and leading automotive and pharmaceutical companies worldwide rely on the results.

Contact Details

North 6th Agency for TLGG

Kevin Pryor

+1 212-334-9753

tlgg@n6a.com

Company Website

https://www.tlggconsulting.com/

View source version on newsdirect.com: https://newsdirect.com/news/tlgg-white-paper-reveals-the-future-of-clinical-trials-is-digital-advises-stakeholders-to-prepare-now-366588448

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.